The "Health Industry Park" of Chengyi Pharmaceutical was completed in September 2019 and was basically put into operation in March 2020. The picture shows an overview of the "Health Industrial Park"
Cheng Yi Pharmaceutical was founded in 1966 and is now a comprehensive modern pharmaceutical enterprise specializing in the production of pharmaceutical capsules, injections, tablets, raw materials, and pharmaceutical intermediates. On March 15, 2017, it landed on the main board of the Shanghai Stock Exchange (stock code: 603811). We have successively won honors such as "Wenzhou Leading Industrial Enterprise", "Wenzhou Most Beautiful Factory", "Wenzhou Mayor Quality Award", "Wenzhou Comprehensive Top 100 Enterprises" and "Top 50 Manufacturing Enterprises", "Zhejiang Provincial Cloud Benchmark Enterprise", and "Provincial Digital Workshop".
As of the end of 2022, the company can produce over 70 varieties and nearly a hundred specifications of drugs, among which the marine biopharmaceutical "glucosamine hydrochloride" series for the treatment and prevention of systemic osteoarthritis, and the nervous system drug "gastrodin" rank among the top in the market share of similar products in China; The high-efficiency diuretic "Tolasemide" series has been included in the national torch program project; The antiviral drug "ribavirin" won the national invention patent award and was included in the national diagnosis and treatment scheme for COVID-19 (fifth to eighth editions). Glucosamine hydrochloride (0.75 grams) won the bid for the third batch of national drug procurement; Tolasemide injection (2ml: 10mg) won the bid for the eighth batch of national drug centralized procurement. The "Chengyi Pharmaceutical Marine Biopharmaceutical Manufacturing Project" (Phase II of the Health Industry Park) with an investment of 1 billion yuan has been basically completed, among which ultra-high purity fish oil EPA soft capsule health food has been successfully listed.
The company took the lead in conducting international certification in 1998, and multiple products have passed certification in multiple countries and regions such as the US FDA, EU EMEA, Australia TGA, UK MHRA, and Mexico COFEPRIS. Since June 2018, the company has established a Shanghai marketing center, 14 provincial and regional offices, and 3 provincial and regional sales departments nationwide. The product sales network covers the whole country, and the international market covers more than 20 countries or regions in Europe, America, India, South Africa, and Southeast Asia.
Comrade Fu Bangwu, the workshop director of the company, was awarded the 2022 National May Day Labor Medal
General Manager Zhao Chunjian accompanied Dongtou District Party Secretary Guo Yunqiang to visit the provincial digital workshop for small capacity injections
Provincial and municipal leaders such as Zhang Dejiang, Li Zemin, Chai Songyue, Yuan Jiajun, Wang Hao, Chen Yijun, Zhao Yide, Liu Xiaotao, Chen Weijun, Yao Gaoguan, and Zhang Zhenfeng also successively inspected Chengyi Pharmaceutical.
The future of Chengyi Pharmaceutical will revolve around the three major development directions of "marine medicine, biopharmaceutical, and traditional Chinese medicine" and the dual goals of "10 billion market value, 100 years of sincerity", accelerate mergers and acquisitions, seize strategic heights, empower enterprises with new value, and achieve company collectivization and high-quality development.